Literature DB >> 25942305

Response to Facciorusso et al.

Xiaobin Feng1, Kuansheng Ma1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25942305     DOI： 10.1038/ajg.2015.83

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  9 in total

1.  A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Authors:  Jiwei Huang; Lvnan Yan; Zheyu Cheng; Hong Wu; Liang Du; Jinzhou Wang; Yinglong Xu; Yong Zeng
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

2.  Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.

Authors:  Hiroyuki Fukuda; Kazushi Numata; Satoshi Moriya; Yu Shimoyama; Tomohiro Ishii; Akito Nozaki; Masaaki Kondo; Manabu Morimoto; Shin Maeda; Kentaro Sakamaki; Satoshi Morita; Katsuaki Tanaka
Journal:  Radiology       Date:  2014-04-02       Impact factor: 11.105

Review 3.  Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma.

Authors:  Kiyoshi Hasegawa; Taku Aoki; Takeaki Ishizawa; Junichi Kaneko; Yoshihiro Sakamoto; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Ann Surg Oncol       Date:  2014-02-25       Impact factor: 5.344

4.  Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: a glimmer of light after the storm trial?

Authors:  Antonio Facciorusso; Nicola Muscatiello; Alfredo Di Leo; Michele Barone
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

5.  Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.

Authors:  Angel E Alsina; Alexia Makris; Vasilios Nenos; Eduardo Sucre; Jade Arrobas; Edson Franco; Nyingi Kemmer
Journal:  Am Surg       Date:  2014-07       Impact factor: 0.688

6.  [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].

Authors:  Xiang-dong Hua; Zhong-ye He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-10

7.  Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.

Authors:  Jan Pfeiffenberger; Ronald Koschny; Katrin Hoffmann; Arianeb Mehrabi; Anne Schmitz; Boris Radeleff; Wolfgang Stremmel; Peter Schemmer; Tom M Ganten
Journal:  Langenbecks Arch Surg       Date:  2013-10-04       Impact factor: 3.445

8.  Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study.

Authors:  Shen-Nien Wang; Shih-Cheng Chuang; King-Teh Lee
Journal:  Hepatol Res       Date:  2013-06-13       Impact factor: 4.288

9.  Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon.

Authors:  Maarten W Nijkamp; Jarmila D W van der Bilt; Menno T de Bruijn; I Quintus Molenaar; Emile E Voest; Paul J van Diest; Onno Kranenburg; Inne H M Borel Rinkes
Journal:  Ann Surg       Date:  2009-05       Impact factor: 12.969
  9 in total
  2 in total

Review 1.  Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.

Authors:  Lumin Chen; Jihong Sun; Xiaoming Yang
Journal:  Cancer Lett       Date:  2015-10-22       Impact factor: 8.679

2.  The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard?

Authors:  Michael Lock; Brandon M Meyers; Amol Mujoomdar
Journal:  Ann Transl Med       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.